XML 75 R56.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets (Narrative) (Details) - USD ($)
 12 Months Ended
Oct. 29, 2013
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Feb. 28, 2014
Acquired Finite-Lived Intangible Assets [Line Items]          
Other revenue, potential upfront payment related to product sales   $ 4,700,000      
Additions to intangible assets   2,556,465 $ 3,101,565 $ 7,462,080  
Amortization of intangible assets   1,989,264 1,596,689 $ 896,156  
Product and License Rights          
Acquired Finite-Lived Intangible Assets [Line Items]          
Intangible assets, gross   18,011,362 16,477,749    
Patents          
Acquired Finite-Lived Intangible Assets [Line Items]          
Intangible assets, gross   8,236,719 8,194,264    
Additions to intangible assets   $ 100,000 3,300,000    
Product, Kristalose | Product and License Rights          
Acquired Finite-Lived Intangible Assets [Line Items]          
Intangible assets, useful life   15 years      
Product Rights Agreement, U.S. Commercialization Rights for Kristalose from Inalco Biochemicals, Inc. and Inalco S.p.A. | Product, Kristalose | Product and License Rights          
Acquired Finite-Lived Intangible Assets [Line Items]          
Product rights agreement, quarterly payments, expiration date   7 years      
Quarterly payments made   $ 1,500,000 $ 1,300,000    
Product, Vaprisol | Product and License Rights          
Acquired Finite-Lived Intangible Assets [Line Items]          
Intangible assets, gross         $ 3,000,000
Pernix Therapeutics | Collaborative Arrangement, Amended International Agreement          
Acquired Finite-Lived Intangible Assets [Line Items]          
Other revenue, potential upfront payment related to product sales $ 4,000,000